On Apr. 22, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer that has spread to other parts of the body. Patients must have received at least two prior therapies before taking Trodelvy.